Sarcoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• JAK 1
• PARP 4
• YAP 0
• EGFR 1
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• CXCR4 0
• FLT3 0
• FTO 0
• HDAC 0

24 of 34+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €2,302,626· until May 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spain· EU contribution €194,075· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, United Kingdom· EU contribution €260,348· until Mar 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting single-cell ploidy from digital pathology images in pan-sarcoma (SImPloidy)

  University College London· London, United Kingdom· EU contribution €276,188· until May 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-IA

  Sustainable 4D hydrogels functionalised with plant-based nanoparticles for bone regeneration in cancer patients (GreenNanoBone)

  The University of Liverpool· Liverpool, United Kingdom· EU contribution €8,649,982· until May 2029· 12 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 18 running projects, newest first. Listed amounts together: €53.4m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Shanghai Pharma Biotherapeutics USA Inc.· Updated 13 Jun 2025

  “Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less than anticipated.”Registry text, quoted unchanged. Source

• Withdrawn

  Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

  NCT05905341· Pfizer· Updated 8 Nov 2023

  “This decision was based on business considerations and not due to specific safety reasons or a request from a regulatory authority.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Pfizer· Source

• Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

  NCT03709680· Pfizer· Source

• Palbociclib and INCMGA00012 in People With Advanced Liposarcoma

  NCT04438824· Memorial Sloan Kettering Cancer Center· Source

• A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

  NCT04238819· Eli Lilly and Company· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 152
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 197
• Machine Learning 28
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Preclinical evaluation of 68Ga-labelled Pt(IV)-DFO complexes as PET-imaging agents for osteosarcoma.

  Eur J Med Chem, Sept 2026

• Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study.

  J Clin Oncol, Aug 2026

• PET radiotracers targeting MDM2 protein interaction: From preclinical validation to first-in-human studies.

  Pharmacol Res, Jun 2026

• Evaluation of standardized uptake value (SUV) and apparent diffusion coefficient (ADC) as prognostic imaging parameters for primary Ewing sarcoma in hybrid 18F-FDG-PET/MRI.

  Eur J Radiol, Jun 2026

• Diagnostic value of integrated 18 F-fluorodeoxyglucose PET/MRI in initial staging and recurrence detection of Ewing sarcoma.

  Nucl Med Commun, Jun 2026

• Current Practices and Variations in the Use of FDG-PET and Bone Marrow Biopsy in Ewing Sarcoma Diagnosis: A Survey of Provider Recommendations.

  J Pediatr Hematol Oncol, Jun 2026

• Mucoid impaction presenting as a solitary pulmonary mass mimicking lung malignancy.

  BMJ Case Rep, Jun 2026

• Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial.

  Magn Reson Imaging, May 2026

• Mass Dose Effects in FAP-Directed Imaging: Influence of Administered Dose of [68Ga]Ga-LNTH-1363S on Image Quality.

  J Nucl Med, Apr 2026

• Synthesis and evaluation of RG7388-based fluorinated MDM2 inhibitors for developing 18F-labeled probes for PET imaging.

  Eur J Med Chem, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.